The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

More than 1 in 3 parents reported that their child has dealt with dental problems linked to a lack of routine oral hygiene, ...

The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday ...

People using weed for medical purposes are as likely -- or more -- to become addicted to cannabis as recreational tokers, a ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

Mifepristone has been under attack by abortion opponents, with several states seeking in federal court to restrict its use.

Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.

The U.S. Department of Health and Human Services has paused public communications until Feb. 1 as Trump appointees take control of health agencies.

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

J&J’s 2025 results will be the launching point for its guidance of 5%-7% revenue growth for 2025-30, which is still well ...

Johnson & Johnson executives, on a Wednesday earnings call, did not provide a timeline for when U.S. Varipulse cases will ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...